A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses, 24(6), 873-80. presented at the 2008 Jun. doi:10.1089/aid.2007.0292. (2008).
Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One, 6(12), e27837. presented at the 2011. doi:10.1371/journal.pone.0027837. (2011).
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events. Hum Vaccin Immunother, 8(5), 630-8. presented at the 2012 May. doi:10.4161/hv.19454. (2012).
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One, 7(8), e41936. presented at the 2012. doi:10.1371/journal.pone.0041936. (2012).
Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS One, 10(5), e0127998. presented at the 2015. doi:10.1371/journal.pone.0127998. (2015).
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis, 215(1), 95-104. presented at the 2017 Jan 01. doi:10.1093/infdis/jiw500. (2017).